SCHEMBL12373520

SCHEMBL12373520

CCn1c(C(C)NS(=O)(=O)c2ccccc2C)cnc1Oc1ccc(C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 4/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
TRIM24 O15164 2/20 0.37
BRD1 O95696 2/20 0.37
BRPF1 P55201 2/20 0.37
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
LMNA P02545 1/20 0.36
CYP2D6 P10635 1/20 0.36
SLC1A3 P43003 1/20 0.35
SLC1A2 P43004 1/20 0.35
SLC1A1 P43005 1/20 0.35
ITGAV P06756 1/20 0.35
FFAR1 O14842 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12373501 0.91 CYP1A2 (0.41) CASP1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL12373704 0.90 CASP1 (0.45) CASP1ITGAVSMN1; SMN2
SCHEMBL12373466 0.90 POLB (0.40) CASP1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL12373547 0.90 PGR (0.40) CASP1MEN1KMT2ASLC1A3SLC1A2
SCHEMBL12373591 0.90 ALDH1A1 (0.38) CASP1MEN1KMT2ACYP1A2CYP2C9
SCHEMBL12373527 0.90 ALDH1A1 (0.43) MEN1KMT2ACYP2C19LMNASMN1; SMN2
SCHEMBL12373463 0.89 MMP13 (0.41) FFAR1SMN1; SMN2
SCHEMBL12373700 0.89 FEN1 (0.39) CASP1MEN1KMT2A
SCHEMBL12373511 0.89 PGR (0.42) CASP1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL12373538 0.88 SLC22A12 (0.40) CASP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE S1PR1, S1PR3, S1PR2 CASP1 1552/4885MEN1 1204/4885KMT2A 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.